Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121381 · ClinicalTrials.gov registry record · Phase 4
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT00121381: Completed Phase 4 study, sponsored by Novartis.
NCT00121381 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 400 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121381, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.
Interventions
- DRUG Pimecrolimus plus topical corticosteroid (TCS)
- DRUG Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
What the finished NCT00121381 record still lists
NCT00121381 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Pimecrolimus plus topical corticosteroid (TCS) is the first listed.
NCT00121381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00121381 about?
NCT00121381 is a clinical study titled "Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis". Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of...
What is the current status of trial NCT00121381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2005-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00121381?
The interventions under investigation include: Pimecrolimus plus topical corticosteroid (TCS) (DRUG), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS) (DRUG).
Who is sponsoring clinical trial NCT00121381?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00121381's enrollment target sits among peer trials
400 211th of 2000 higher than 1,784 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia